The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
Clinical trial NCT07240194 · RECRUITING
Trial details
- NCT number
- NCT07240194
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-01
- Primary completion
- 2028-12-30
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.